EPO Patent Bulletin - Pharma (A61K)

PD-1 Antibodies, Nanjing Legend Biotech, 8th Apr

PD-1 Antibodies, Nanjing Legend Biotech, 8th Apr

Phosphoantigen Prodrug Compounds

The European Patent Office granted patent EP3818064A1 for phosphoantigen prodrug compounds to University College Cardiff Consultants Ltd. and University of Birmingham. The patent covers novel chemical compounds with applications in immunology and oncology, classified under IPC C07F 9/44 and A61K 31/664. The patent is valid in 44 designated contracting states across Europe.

TNF Inhibitor for Gastrointestinal Disease Treatment, EP3810095A1

The EPO published patent application EP3810095A1 for BT Bidco, Inc., covering a TNF inhibitor formulation for treating gastrointestinal diseases. The patent application was published under IPC classifications A61K 9/22, A61K 31/436, and A61K 48/00. The application designates all EU member states plus other EPC contracting states including CH, GB, LI, MC, NO, TR, and IS.

Hydrocortisone for Treatment of Mastitis in Non-Human Mammals, EP3829591A1

The European Patent Office published Patent Application EP3829591A1 for VIRBAC covering hydrocortisone formulations for treating mastitis in non-human mammals. The application names inventors HAVRILECK Bertrand, JASMIN Pierre, and MCGAHIE David with IPC classifications in A61K therapeutic preparations. The designated states cover EU contracting states including AT, BE, DE, ES, FR, GB, IT, NL, PL, and others.

Compounds, Compositions, Methods, and Uses for Treating Cancer and Immunological Disorders

The European Patent Office granted Patent EP3820533A2 to IL-2RX, Inc. covering novel compounds and compositions for treating cancer and immunological disorders. The patent application, filed by inventors Soares and Hurt, was published April 8, 2026 under IPC classifications A61K 47/64, A61K 47/65, A61P 35/00, and A61P 37/02. The patent is designated for all EU member states and extended territories.

Thiocycloheptyne Derivatives and Their Use

The EPO published European patent application EP3820858A1 for thiocycloheptyne derivatives and their pharmaceutical use, filed by Cristal Delivery B.V. The patent covers thiocycloheptyne compound compositions and their therapeutic applications under IPC classification A61K. The patent is validated in all designated EU contracting states including Germany, France, the United Kingdom, Italy, Spain, and 24 other jurisdictions.

Immunoglobulin antibody against RSV prefusion F protein, published 8th Apr

Immunoglobulin antibody against RSV prefusion F protein, published 8th Apr

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES

The European Patent Office granted Patent EP3244930A1 to the University of Southern California on April 8, 2026. The patent covers pharmaceutical compositions comprising POH derivatives for therapeutic applications including cancer treatment. The patent is designated across 38 European member states including DE, FR, GB, IT, ES, NL, BE, and others.

Bi-Specific Cancer Treatment Constructs with Different Epitope Binding

The European Patent Office published patent application EP3484516A1 assigned to Fred Hutchinson Cancer Center on April 8, 2026. The patent covers bi-specific binding domain constructs with different epitope binding properties for treating cancer. The technology falls under IPC classifications A61K 39/395, C07K 16/28, and C12N 15/09, with designated states covering major European markets.

TLR4 Antagonist Patent for Multiple Myeloma Treatment EP3558323A1

The European Patent Office granted patent EP3558323A1 for specific TLR4 antagonists in the treatment of multiple myeloma. The patent applicants include Etablissement Français du Sang, CNRS, Université Paul Sabatier Toulouse III, and INSERM. Designated states cover all EU member states plus other EPC contracting states.

Novel Recombinant Protein UK114 in Stable Polymer Form for Tumour Treatment

The European Patent Office granted Patent EP3554639A1 to Alberto Bartorelli Cusani for a novel recombinant protein UK114 in stable polymer form designed for the treatment or prevention of malignant solid and systemic tumours. The patent covers pharmaceutical compositions containing the recombinant protein and methods of treatment. The patent is classified under A61K 38/50 and related pharmaceutical categories.

Bispecific Anti-TRAILR2 and Anti-CDH17 Binding Molecules for Cancer Treatment - EP3559040A2

The EPO published patent application EP3559040A2, filed by Boehringer Ingelheim International GmbH, covering bispecific binding molecules that simultaneously target TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) and CDH17 (cadherin 17) for the treatment of cancer. The patent application was published on April 8, 2026 and is classified under IPC categories C07K 16/28, A61K 39/395, A61P 35/00, and C12N 15/62. The application designates all EPO contracting states covering major European pharmaceutical markets.

Polyglutamated Antifolates and Uses Thereof (EP3496757A1)

The European Patent Office published patent application EP3496757A1 for polyglutamated antifolates and their therapeutic uses, filed by L.E.A.F Holdings Group LLC. The patent covers compositions for treating cancer and inflammatory conditions. The application was published April 8, 2026, designating 36 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states. No compliance deadlines or penalties are specified.

Fibrous Dosage Form EP3500242A1

The European Patent Office published patent application EP3500242A1 titled 'Fibrous Dosage Form' on April 8, 2026. The patent application, filed by applicant Aron H. Blaesi with inventors Blaesi and Nannaji Saka, covers pharmaceutical dosage formulations classified under IPC A61K. The application designates multiple European member states for patent protection.

EP3283091A1 - Berry Extraction Method Using Alkaline Magnesium Compound

The European Patent Office granted Patent EP3283091A1 to inventor Reijonen, Mika Tapio. The patent covers a method of extracting berries or fruits using an alkaline magnesium compound for use in pharmaceutical, herbal, nutritional, or cosmetic ingredients. The patent is valid in 38 designated European states.

Artificial Sweat Composition, EP3355853A1, Apr 08

Artificial Sweat Composition, EP3355853A1, Apr 08

Shiseido Skin Glow Evaluation Method Patent EP3219302A1

The European Patent Office published Shiseido Company Ltd.'s patent application EP3219302A1 covering methods for evaluating skin glow, methods for examining skin glow improving agents, and skin glow improving compositions. The patent application was published on April 8, 2026, designating 37 European states including DE, FR, GB, IT, ES, and others. The application includes inventors Masuda Yuji, Yagi Eiichiro, and Kuwahara Tomohiro.

Long-Acting Injectable Formulations Comprising an Isoxazoline Active Agent (EP3261617A1)

The European Patent Office published European patent application EP3261617A1 for Boehringer Ingelheim Vetmedica GmbH covering long-acting injectable formulations comprising isoxazoline active agents. The application classifies under IPC codes A61K 31/422, A61K 31/42, A61K 9/00, and A01N 43/80. The application designates 36 European contracting states including Germany, France, United Kingdom, Italy, Spain, and other EU member states.

Pharmaceutical Composition Comprising Lipoic Acid and Taurine as Osmoprotective Agent

The EPO granted Patent EP3297733A1 to Dulcis Health Science for a pharmaceutical composition combining lipoic acid and taurine as an osmoprotective agent. The patent, published April 8, 2026, lists inventors Claret, Martine, Claret, Claude, and Chatard-Baptist, Caroline, with designations covering all 31 European Patent Convention member states.

Cinnamyl Alcohol Derivative for Appetite Reduction

The European Patent Office published application EP3474833A1 for Symrise AG covering a cinnamyl alcohol derivative for reducing appetite and generating satiety. The invention lists Veronika Somoza, Barbara Lieder, Katrin Geissler, Joachim Hans, Kathrin Langer, Jakob Peter Ley, and Sabine Widder as inventors. The application classifies under A61K 31/015, A61K 31/185, and A61K 31/215. Validated designated states include DE, FR, GB, IT, ES, NL, and other EPC contracting states.